Medindia

X

/C O R R E C T I O N -- CeloNova BioSciences, Inc./

Saturday, October 31, 2009 General News J E 4
Advertisement

In the news release, French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent, issued today, Oct. 30, 2009, by CeloNova BioSciences, Inc., over PR Newswire, the second paragraph should read:

The study will evaluate the short-, mid- and long-term safety and efficacy of the CATANIA™ coronary stent for the treatment of up to three de novo native coronary artery lesions in a real world setting. “Professor Teiger and Doctor Barragan are independent and respected interventional cardiologists and we look forward to the results of their study,” said Thomas A. Gordy, President and Chief Executive Officer of CeloNova BioSciences. “Physicians throughout France have already used the CATANIA™ stent, but this registry will increase participation over a broad spectrum of new facilities and give patients access to a stent without drugs on the surface and for which they do not have to take long-term dual antiplatelet therapy.”

Complete, corrected release follows:

French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent

NEWNAN, Ga., Oct. 30 -- Physicians at more than 40 centers in France have joined a study of the CATANIA™ Coronary Stent with NanoThin Polyzene®-F manufactured by CeloNova BioSciences. With Professor Emmanuel Teiger and Doctor Paul Barragan as co-Principal Investigators, the researchers today announced the Assessment of The Latest Non-Thrombogenic Angioplasty (ATLANTA-France) stent study. Each center will enroll 50 patients with the first procedures expected in early November.

(Photo:  http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-b )

(Photo:  http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-a )

The study will evaluate the short-, mid- and long-term safety and efficacy of the CATANIA™ coronary stent for the treatment of up to three de novo native coronary artery lesions in a real world setting. “Professor Teiger and Doctor Barragan are independent and respected interventional cardiologists and we look forward to the results of their study,” said Thomas A. Gordy, President and Chief Executive Officer of CeloNova BioSciences. “Physicians throughout France have already used the CATANIA™ stent, but this registry will increase participation over a broad spectrum of new facilities and give patients access to a stent without drugs on the surface and for which they do not have to take long-term dual antiplatelet therapy.”

The CATANIA™ stent is CE Marked and available throughout the European Union, in the Middle East, and Northern Africa. The stent, treated with CeloNova's anti-thrombotic and bacterial resistant Polyzene®-F surface is available in 60 sizes.

About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova develops novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment. The Company's current products include Embozene™ Color-Advanced Microspheres and the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. Embozene™ Microspheres have been approved by the FDA for the treatment of hypervascular tumors and arteriovenous malformations. For more information, please visit www.celonova.com

SOURCE CeloNova BioSciences, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
BYETTA Approved for Expanded Use as First-Line Tre...
S
Dr. Eliscer Guzman From The Mount Sinai Hospital a...